Painful and painless myocardial ischemia detected by elevated level of high-sensitive troponin in patients with hypertrophic cardiomyopathy by Gębka, Adam et al.
195Advances in Interventional Cardiology 2018; 14, 2 (52)
Short communication
Corresponding author: 
Paweł Petkow-Dimitrow MD, PhD, Second Department of Cardiology, Jagiellonian University Medical College, 17 Kopernika St, 31-501 Krakow, 
Poland, phone: +48 12 424 71 70, e-mail: dimitrow@mp.pl 
Received: 7.03.2018, accepted: 11.04.2018.
Painful and painless myocardial ischemia detected  
by elevated level of high-sensitive troponin in patients 
with hypertrophic cardiomyopathy 
Adam Gębka1, Renata Rajtar-Salwa1, Artur Dziewierz2, Paweł Petkow-Dimitrow2
1Second Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland 
2Second Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
Adv Interv Cardiol 2018; 14, 2 (52): 195–198
DOI: https://doi.org/10.5114/aic.2018.76413
Introduction
High-sensitivity troponin I  (hs-TnI), an extra-precise 
biomarker for the detection of even small myocardial injury 
caused by ischemia, has been successfully used in patients 
with hypertrophic cardiomyopathy (HCM) [1, 2]. In the 
most recent studies [3, 4], measurements of hs-TnI levels 
were synchronized with a noninvasive assessment of he-
modynamic parameters in the following way: first, resting 
echocardiography (including a  provocative maneuver to 
induce a left ventricular outflow tract (LVOT) gradient) was 
performed, followed by ambulatory electrocardiography 
(ECG) Holter monitoring with devices which allow potential 
episodes of angina pectoris to be marked by the patients. 
After the 24-hour ECG Holter monitoring in conditions of 
typical everyday physical activity, the measurement of hs-
TnI level was immediately performed. Interestingly, the 
biomarker level had a close time relationship with findings 
on Holter monitoring [3] and echocardiography [4].
High-sensitivity troponin I levels were associated with 
both an increased heart rate during Holter monitoring 
[3] and a provoked LVOT gradient [4] (stimuli provoking 
myocardial ischemia). These findings are corroborated by 
previous studies in invasive and nonphysiological, atrial 
pacing stressors [5–7].
From the technical point of view, in patients with 
HCM, verification of angina pectoris by resting or exer-
cise ECG is practically impossible because of common 
abnormalities visible on resting ECG (with ischemic-like 
changes or significant deformation of the QT complex).
Aim
Nowadays, hs-Tn level measurement seems to be ide-
al for precise verification of myocardial injury due to the 
occurrence of ischemia in patients with HCM. The aim 
of this study was to collect information about episodes 
of angina pectoris occurring in the 24-hour period pre-
ceding the hs-TnI level measurement, both in outpatients 
from a  clinic and patients hospitalized due to cardiac 
signs and symptoms.
Material and methods
A group of 100 consecutive patients with HCM, both 
from ambulatory care and admitted to the clinic due to 
cardiac signs and symptoms (pooled group), were recruit-
ed to the study. Patients from our previous ambulatory 
studies were included in the current study; however, the 
present investigation is different from the previous one 
[3, 4] and is based on the history of angina pectoris with-
in 24 h before the hs-TnI measurement. We attempted 
to investigate a  full spectrum of patients from asymp-
tomatic ones to those with severe symptoms requiring 
hospitalization. Most patients received pharmacothera-
py (Table I).
The exclusion criteria were as follows: (a) ST-segment 
or non-ST-segment elevation myocardial infarction (cur-
rent or previous), (b) previous septal alcohol ablation for 
LVOT gradient reduction, (c) significant coronary stenosis 
on coronary angiography or (d) renal failure, (e) diabetes 
mellitus, and (f) regular sports activity. We used criteria 
a, b, c to exclude patients with concomitant atheroscle-
rotic stenosis/occlusion of epicardial coronary arteries. 
We wanted to include only patients with small vessel dis-
ease, which is a common abnormality in HCM at any age. 
In such pathology, ischemia may be induced by coronary 
microvasculature abnormalities superimposing on other 
provoking factors – massive LV hypertrophy, LVOT gradi-
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ent, tachycardia. Renal failure is a common extra-cardiac 
factor responsible for TnI elevation. Regular sports activi-
ty may induce repetitive ischemia in the predisposed pa-
tients. This issue requires further investigation. Diabetes 
mellitus may be associated with silent ischemia from epi-
cardial coronary arteries (necessity of exclusion of pain-
less macrovascular stenosis).
The final sample included 73 patients with HCM (age: 
42 ±10 years; 40 men and 33 women). Ambulatory pa-
tients were asked to maintain normal physical activity 
during the 24-hour period before the hs-TnI level mea-
surement. In hospitalized patients, the history of cardiac 
symptoms in the 24-hour period before admission was 
taken, and, finally, the hs-TnI level was measured at ad-
mission. The cut-off value 19  ng/l was used according 
to the producer’s instructions (bioMerieux VIDAS High 
sensitive Troponin I). The 99th percentile of a presumably 
healthy population, the recommended cut-off has been 
defined at 19 ng/l.
Patients were divided into 2 groups: hs-TnI-positive 
and hs-TnI-negative. In the next stage, the group with 
the elevated level of hs-TnI was divided into 2 further 
subgroups: one with angina pectoris (painful ischemia 
(AP+)) and the other without angina pectoris (painless, 
silent ischemia (AP–)). The study protocol was approved 
by a local institutional review board.
Statistical analysis
Continuous variables were presented as mean (SD) or 
median (interquartile range – IQR). The levels of hs-TnI 
between AP+ and AP– were compared by the Mann-Whit-
ney test. The majority of echocardiographic parameters 
with normal distribution (according to the Kolmogor-
ov-Smirnov test) were compared using Student’s t-test. 
For comparison of one echocardiographic parameter the 
Mann-Whitney test was used. A p-value of < 0.05 was 
considered statistically significant.
Results
Baseline characteristics of 73 patients are presented 
in Table I.
Hs-TnI was detected in all patients (range: 1.5–40,000 
ng/l). Increased levels were revealed in 35 patients (tro-
ponin-positive group), and “normal-low” levels in 38 pa-
tients (troponin-negative group). A  total of 17 patients 
from the troponin-positive subgroup had perceptible an-
gina pectoris (AP+) and the remaining 18 patients were 
without angina pectoris (AP–). The level of troponin was 
significantly higher in the AP+ subgroup in comparison 
with the AP– subgroup (median, IQR: 100.2 ng/l, 60.1–
1640.0 ng/l vs. 36.4 ng/l, 20.5–70.1 ng/l; p = 0.027). In 
the troponin-negative subgroup, 3 out of 38 patients 
(7.7%) had a  short episode of mild angina pectoris in 
the first hours of the 24-hour period (the measurement 
of hs-TnI levels was probably performed after the peak 
value in a decreasing phase of the time profile of hs-TnI 
release). 
There were no differences in echocardiographic pa-
rameters between AP– and AP+ subgroups (only echo-
cardiographic parameters were synchronously measured 
with hs-TnI) (Table II).
Discussion
According to the third universal definition of myo-
cardial infarction from 2012, a (nearly) normal coronary 
angiogram does not exclude acute coronary syndrome 
[8]. The guidelines defined the mechanism of type 2 
myocardial infarction as secondary to ischemic imbal-
ance causing myocardial injury with necrosis where con-
ditions other than coronary contribute to the imbalance 
between myocardial oxygen supply and/or demand. In 
HCM, the potential mechanism of myocardial ischemia 
includes: hypertrophied myocardium, coronary microvas-
cular disease, tachycardia, and increased LVOT gradient. 
In our group, almost 50% of the patients had a positive 
hs-TnI test result, out of which approximately 25% had 
silent ischemia and 25% had painful angina pectoris 
(in this group, the median value of hs-TnI was elevated 
> 5 × normal value, i.e. a significant level). These values 
Table I. Baseline characteristics (n = 73)
Variable Value
Ejection fraction, mean ± SD (%) 62.4 ±9.2
Maximum LV thickness, mean ± SD [mm] 21.4 ±4.8
Resting LVOT gradient, mean ± SD [mm Hg] 27.11 ±16.53
Resting LVOT gradient, > 30 mm Hg, n (%) 20 (27.4)
Left atrial diameter, mean ± SD [mm] 48.7 ±10.2
LV end-diastolic diameter, mean ± SD [mm] 42.5 ±7.9
Episode of angina pectoris during 24 h  
before hs-TnI measurement (ambulatory,  
hospitalization), n (%) 
20 (27.4)
Dyspnea at any time, n (%) 39 (53.2)
Syncope at any time, n (%) 18 (24.6)
NSVT at any time, n (%) 24 (32.8)
Sudden death in family history, n (%) 19 (26)
Creatinine, mean ± SD [µg/l] 89.1 ±12.5
Drugs used during analyzed 24-hour period, n (%):




hs-TnI – high-sensitivity troponin I, LVOT – left ventricular outflow tract, LV – left 
ventricular, NSVT – nonsustained ventricular tachycardia.
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are alarming and important. Recently, it has been pro-
posed that stress echocardiography has a  significant 
prognostic role in patients with HCM, with ischemic end-
points showing a greater predictive accuracy than hemo-
dynamic ones [9].
Until 2017, both United States and European guide-
lines for exercise and sports participation in patients 
with HCM had issued consistent recommendations 
against participation in all kinds of low-intensity com-
petitive sports and even advised not to undertake vigor-
ous activities on a recreational basis. However, recently, 
exercises such as long-term training, fitness, and sports 
activity were reported as beneficial in patients with HCM 
[10, 11].
Based on the association between the elevated tro-
ponin level in patients with HCM and (i) tachycardia, 
(ii) nonsustained ventricular tachyarrhythmia (NSVT) [3], 
(iii) resting and provoked LVOT gradients [4], (iv) high 
risk for sudden cardiac death [12] and symptomatic an-
gina pectoris (described in this study), we may suggest 
that any exercise in these patients (performed either for 
training or diagnostic purposes) should be monitored by 
frequent troponin level measurements after the exercise 
test (4, 8, 12 and 24 h after exercise). The proposed time 
profile of troponin sampling has been partly based on 
a  very recent publication in a  highly selected group of 
preclinical HCM patients [13] where after exercise the 
first and only hs-TnI measurement was performed 4 h 
after stress. We propose a more detailed time profile to 
detect peak value hs-TnI after exercise.
The most important subgroup is that of patients 
with silent myocardial ischemia (approximately 25%), 
who should be discouraged from training (due to lack of 
awareness of induction of ischemia).
Our study has several limitations. First, the number 
of included patients was limited by several exclusion cri-
teria. Next, the current pharmacological treatment was 
maintained; particularly β-blockers were not withdrawn 
in ambulatory patients as our preliminary study showed 
that β-blocker withdrawal might not be safe in this group 
of patients. 
The next limitation is the fact that only echocardio-
graphic parameters were synchronously measured with 
hs-TnI. Another limitation is the evidence that although 
the major mechanism of troponin release is ischemia 
with myocardial injury there are several other mecha-
nisms, as reported by White [14]. Finally, two more limita-
tions are the lack of imaging both for stress test induced 
ischemia and stress resulting in ischemic injury (i.e. late 
enhancement in cardiac magnetic imaging reported by 
Grommans and Cramer) [15]. In this preliminary study, 
we aimed to assess hs-TnI (frequency of painful/pain-
less ischemia) only in patients not exposed to unnatural 
stress conditions (for logistic and ethical reasons). Pre-
viously we observed the release of hs-TnI after natural, 
spontaneous stressors such as supraventricular [16] and 
ventricular tachycardia [17].
Conclusions
We confirmed that the assessment of the hs-TnI lev-
el is useful to monitor a  full spectrum of patients with 
HCM (from asymptomatic patients to those with severe 
symptoms). Approximately 25% of the patients had angi-
na pectoris with significantly elevated hs-TnI levels, and 
approximately 25% had silent myocardial ischemia with 
slightly/moderately elevated hs-TnI levels. The echocar-
diographic parameters did not differ between the painful 
and painless subgroup of patients.
From a  clinical perspective, these findings suggest 
the need to improve pharmacological/nonpharmacolog-
ical management of patients with HCM and discourage 
systematic physical activity in the troponin-positive sub-
group (considering the third universal definition of myo-
cardial infarction).
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